Millennium Management
DSGN icon

Millennium Management’s Design Therapeutics DSGN Stock Holding History

Millennium Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-34,700
Closed -$200K – 6205
2023
Q1 		$200K Sell
34,700
-35,600
-51% -$266K ﹤0.01% 5168
2022
Q4 		$721K Buy
70,300
+30,300
+76% +$411K ﹤0.01% 4450
2022
Q3 		$669K Buy
+40,000
New +$796K ﹤0.01% 4700

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management's DSGN Position: Q2 2026 in Review

Millennium Management increased its Design Therapeutics (DSGN) stake by 36% in Q2 2026, buying an estimated $484K and bringing the position to 147,714 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #3764.

Millennium Management first reported a position in DSGN in Q1 2021 and has held it in 16 quarters since. The position peaked at $7.57M in Q1 2021. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Millennium Management held 147,714 shares of Design Therapeutics worth $2.14M as of Q2 2026.
  • Millennium Management bought 38,786 Design Therapeutics shares in Q2 2026, an estimated $484K.
  • Design Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #3764 holding.
  • Millennium Management first reported a position in Design Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • Millennium Management's Design Therapeutics position peaked at $7.57M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.